HOXC10 | Homeobox C10 | Transcription factors
| | | | | Tissue enhanced |
HOXC9 | Homeobox C9 | Transcription factors
| | | | | Tissue enhanced |
HS3ST5 | Heparan sulfate (glucosamine) 3-O-sulfotransferase 5 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
HSPB2 | Homo sapiens heat shock 27kDa protein 2 (HSPB2), mRNA. | | | | | | Tissue enhanced |
HSPB2-C11orf52 | HSPB2-C11orf52 readthrough (NMD candidate) | | | | | | Tissue enhanced |
HSPB6 | Heat shock protein, alpha-crystallin-related, B6 | | | | | | Tissue enhanced |
HSPB7 | Heat shock 27kDa protein family, member 7 (cardiovascular) | | | | | | Tissue enhanced |
IP6K3 | Inositol hexakisphosphate kinase 3 | Enzymes
| | | | | Tissue enhanced |
ITGB6 | Integrin, beta 6 | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JPH2 | Junctophilin 2 | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
KCNQ5 | Potassium voltage-gated channel, KQT-like subfamily, member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNS3 | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNT1 | Potassium channel, subfamily T, member 1 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KLHL30 | Kelch-like family member 30 | | | | | | Tissue enhanced |
KY | Kyphoscoliosis peptidase | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enhanced |
LINC00346 | Long intergenic non-protein coding RNA 346 | | | | | | Tissue enhanced |
LINGO4 | Leucine rich repeat and Ig domain containing 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
LMCD1 | LIM and cysteine-rich domains 1 | | | | | | Tissue enhanced |
MAMSTR | MEF2 activating motif and SAP domain containing transcriptional regulator | | | | | | Tissue enhanced |
MSTN | Myostatin | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
MTRNR2L12 | MT-RNR2-like 12 (pseudogene) | | | | | | Tissue enhanced |
MTRNR2L8 | MT-RNR2-like 8 | | | | | | Tissue enhanced |
MTRNR2L9 | MT-RNR2-like 9 (pseudogene) | Predicted secreted proteins
| | | | | Tissue enhanced |
MYF5 | Myogenic factor 5 | Transcription factors
| | | | | Tissue enhanced |
MYH13 | Myosin, heavy chain 13, skeletal muscle | Plasma proteins
| | | | | Tissue enhanced |
MYH8 | Myosin, heavy chain 8, skeletal muscle, perinatal | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
NANOS1 | Nanos homolog 1 (Drosophila) | Disease related genes
| | | | | Tissue enhanced |
NEURL1 | Neuralized E3 ubiquitin protein ligase 1 | | | | | | Tissue enhanced |
NEXN | Nexilin (F actin binding protein) | Cytoskeleton related proteins Disease related genes
| | | | | Tissue enhanced |
P2RX6 | Purinergic receptor P2X, ligand-gated ion channel, 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY2 | Purinergic receptor P2Y, G-protein coupled, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PACSIN3 | Protein kinase C and casein kinase substrate in neurons 3 | Plasma proteins
| | | | | Tissue enhanced |
PADI2 | Peptidyl arginine deiminase, type II | Enzymes
| | | | | Tissue enhanced |
PAX3 | Paired box 3 | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
PAX7 | Paired box 7 | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
PDLIM3 | PDZ and LIM domain 3 | Plasma proteins
| | | | | Tissue enhanced |
PEBP4 | Phosphatidylethanolamine-binding protein 4 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PGPEP1L | Pyroglutamyl-peptidase I-like | Enzymes
| | | | | Tissue enhanced |
PHKA1 | Phosphorylase kinase, alpha 1 (muscle) | Disease related genes
| | | | | Tissue enhanced |
PIGY | Phosphatidylinositol glycan anchor biosynthesis, class Y | Predicted membrane proteins
| | | | | Tissue enhanced |
PITX2 | Paired-like homeodomain 2 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
PKIA | Protein kinase (cAMP-dependent, catalytic) inhibitor alpha | | | | | | Tissue enhanced |
PLEKHF1 | Pleckstrin homology domain containing, family F (with FYVE domain) member 1 | | | | | | Tissue enhanced |
PPM1J | Protein phosphatase, Mg2+/Mn2+ dependent, 1J | Enzymes
| | | | | Tissue enhanced |
PPP1R1A | Protein phosphatase 1, regulatory (inhibitor) subunit 1A | | | | | | Tissue enhanced |
PPP1R3C | Protein phosphatase 1, regulatory subunit 3C | | | | | | Tissue enhanced |
PPP2R3A | Protein phosphatase 2, regulatory subunit B'', alpha | | | | | | Tissue enhanced |
PRKCQ | Protein kinase C, theta | Cancer-related genes Enzymes Plasma proteins
| | | | | Tissue enhanced |
PRPH2 | Peripherin 2 (retinal degeneration, slow) | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
PRSS45 | Protease, serine, 45 | Enzymes
| | | | | Tissue enhanced |